In April 2016, the FDA approved the first and only therapeutic products for corneal cross-linking, a minimally invasive outpatient procedure for the treatment of progressive keratoconus. Corneal cross-linking stiffens corneas that have been weakened by the disease. Corneal cross-linking offers and effective treatment for patients who, until 2016, had no therapeutic options to limit the progression of this sight-threatening disease.
As a cornea specialist, Dr. Rick Palmon is the first ophthalmologist in Southwest Florida to provide corneal cross-linking to patients.